Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional Profiles

• 資料種別: 博士論文
• タイトル: Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional Profiles
• 著者・編者: 荒木, 智徳
• 著者標目: 荒木, 智徳
• 出版事項: MDPI
• 出版年月日等: 2022-12-07
• 出版年（W3CDTF）: 2022-12-07
• 並列タイトル等: PARP阻害剤と5-アザデオキシシチジンの併用によるがん細胞への細胞傷害性増強とその転写プロファイルの違いについて
• タイトル（掲載誌）: Cancers
• 巻号年月日等（掲載誌）: 14 17
• 掲載巻: 14
• 掲載号: 17
• 掲載ページ: 4171-
• ISSN（掲載誌）: ISSN : 2072-6694
• 授与機関名: Nagasaki University (長崎大学)
• 授与年月日: 2022-12-07
• 報告番号: 甲医歯薬第1471号
• 学位: 博士(医学)
• 本文の言語コード: eng
• 件名標目: PARP inhibitor; 5-aza-20-deoxycytidine; microarray; transcription; DNA methylation
• 対象利用者: 一般
• 一般注記: Poly(ADP-ribose) polymerase (PARP) is involved in DNA repair and chromatin regulation. 5-Aza-2′-deoxycytidine (5-aza-dC) inhibits DNA methyltransferases, induces hypomethylation, blocks DNA replication, and causes DNA single strand breaks (SSBs). As the PARP inhibitor is expected to affect both DNA repair and transcriptional regulations, we investigated the effect of combinational use of PARP inhibitors on cytotoxicity of 5-aza-dC in human cancer cell lines. The combinational treatment of 5-aza-dC and PARP inhibitor PJ-34 exhibited a stronger cytotoxicity compared with their treatment alone in blood cancer HL-60, U937, and colon cancer HCT116 and RKO cells. Treatment with 5-aza-dC but not PJ-34 caused SSBs in HCT116 cell lines. Global genome DNA demethylation was observed after treatment with 5-aza-dC but not with PJ-34. Notably, in microarray analysis, combinational treatment with PJ-34 and 5-aza-dC caused dissimilar broad changes in gene expression profiles compared with their single treatments in both HCT116 and RKO cells. The profiles of reactivation of silenced genes were also different in combination of PJ-34 and 5-aza-dC and their single treatments. The results suggest that the combinational use of 5-aza-dC and PARP inhibitor may be useful by causing distinct transcriptional profile changes.; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1471号 学位授与年月日:令和4年12月7日; Author: Tomonori Araki, Kensuke Hamada, Aung Bhone Myat, Hideki Ogino, Kohei Hayashi, Miho Maeda, Ying Tong, Yasufumi Murakami, Kazuhiko Nakao and Mitsuko Masutani; Citation: Cancers, 14(17), art.no. 4171; 2022; identifier:Nagasaki University (長崎大学), 博士(医学) (2022-12-07)
• 一次資料へのリンクURL: fulltext; https://nagasaki-u.repo.nii.ac.jp/?action=repository_action_common_download&item_id=27893&item_no=1&attribute_id=70&file_no=1
• オンライン閲覧公開範囲: インターネット公開
• 著作権情報: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• 関連情報: http://hdl.handle.net/10069/00041978
• 関連情報（DOI）: 10.3390/cancers14174171
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 長崎大学 : 長崎大学学術研究成果リポジトリ